AhmedGalalMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Physician

Dr. Galal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact

PubMed

2 citations
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2025-02-10
2 citations
Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.
Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder
Blood Advances. 2025-01-14
2 citations
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10

Leukemia Cure We’re Waiting for? Patient Cancer-Free for 11 Years After Innovative TreatmentJune 11th, 2022
Leukemia Cure? Patient Still Cancer-Free 11 Years After Innovative TreatmentJune 9th, 2022
The World Needs a Breakthrough YearJune 7th, 2021